We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2018 10:46 | This pattern puzzles me. Saw results yesterday shortly after announcement. They looked fine to me and the share price went up to about 1596. By mid afternoon, when I left the house, the price appeared to stabilise around 1575. Still ok. When I came home the price had closed 14p down on the day. Two analysts raised their guidance this morning, but price dropped another 45p, leaving price down 100p below yesterday’s opening price. Was a just a bad day for Pharma? No not at all. AZN up 3% this morning without world shatteringly good news.BTG also up. What was so bad about GSK that the price has fallen so much on what most thought were a decent set of figures??? | jadeticl3 | |
26/7/2018 10:24 | I agree with Monty re. the proxy Bond thing. Was in it for a short time without conviction until 14th June because of the "cheap" price back in December. But 22 times price to book seems awfully high risk and it seems the source of income is always a battle to find the next thing. Meanwhile you have investment trusts that yield 6 to 8% at a price to book of one and their income, be it wind turbines or office lets, isn't reliant on research and development. | stewart64 | |
26/7/2018 10:24 | Summer holiday movements, often exaggerated it’s all good in the hood, markets always presenting opportunities to buy or sell, better buying down here that yesterday above 1580p! | ny boy | |
26/7/2018 10:14 | @zho 23andme had a representative at investor call, he appeared to be clued up. Hopefully they can help GSK execute cheaper, faster trials. | romeike | |
26/7/2018 10:10 | I guess some didn't bother to check the dividend calendar before bailing out. Worth noting the last few ex-div days GSK finished close to where it started - cash for free. | romeike | |
26/7/2018 10:09 | Placing its trust in a gene profiling group backed by Google is a promising plan | zho | |
26/7/2018 10:07 | Not understanding the over reaction to not getting the extended approval for Nucala, it would have been a nice bonus but it's hardly a game changer either way. If anything it is a shame for patients as one of the trials definitely showed it worked. | romeike | |
26/7/2018 09:57 | Buying now - I think there is a fundamental shift in management and strategy. Why change dividend policy? | rsharman | |
26/7/2018 09:47 | Well if Monty is selling at £15, I would call that a buy signal | lurker | |
26/7/2018 09:33 | I sold my GSK for me really ordinary shares like a bond, but with extra risk. You know every year 80p because they never increase, that's if they maintain.With a corporate bond you know you got priority over ord shares dividends on payment. | montyhedge | |
26/7/2018 09:32 | Added more 1500p all a bit silly really but I like collecting 19p quarterly divis | ny boy | |
26/7/2018 09:28 | That is the danger, can they maintain. | montyhedge | |
26/7/2018 08:42 | Level TraderM? | ny boy | |
26/7/2018 08:28 | Waiting for now..... ;0) | tradermichael | |
26/7/2018 08:21 | Added a few more 1510p, in the long term portfolio. | ny boy | |
26/7/2018 08:08 | 1540 broken - rns this morning not good news plus continued momentum from yesterday - Key figure (IMO0 will be 1500 - If breaks then will be a watch and wait job (imo) | pugugly | |
26/7/2018 07:12 | Few got leaks about this morning’s news then, reversal day yesterday, looking to see if 1540p support holds, any open much lower and I will add more with ex div coming up next week. | ny boy | |
25/7/2018 20:01 | GlaxoSmithKline 2018 Q2 - Results - Earnings Call Slides | fangorn2 | |
25/7/2018 16:39 | Possibly a read bbetween the lines that current 80p p/a dividend at risk - Came over to me in the presentation during exposition of cash flow on dividend payments and comment that had to improve before dividends started growing again - The unspoken message could have been that dividend levek was not sacred in 2019 and might actually fall. Anyone else get teh same feeling ? | pugugly | |
25/7/2018 16:29 | FTSE getting hit by Sterling - ii's seem to think UK becoming a vassal state is a good thing. | romeike | |
25/7/2018 16:23 | strange day | davemac3 | |
25/7/2018 16:18 | More focus on oncology and immunology, excellent. | romeike | |
25/7/2018 15:23 | Even the results call intermission music is a lot better ! ;p p.s I had absolutely no issue registering - piece of cake! | romeike | |
25/7/2018 14:20 | Front end login registration terrible - Keeps on asking you to register when already registerd. 4/10 for clarity. | pugugly | |
25/7/2018 14:01 | good post. please post on UKIP EU politics threads. | thecurryqueen |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions